Introduction
The cytochrome P450 3A (CYP3A) enzyme is involved in the metabolism of both endogenous substances and xenobiotics, and accounts for the metabolism of over 50% of clinically used drugs. 1 CYP3A consists of four genes, CYP3A4, CYP3A43, CYP3A5 and CYP3A7, located on 7q21-7q22.1. 2 The CYP3A5 gene is the major class representing about 50% of the hepatic CYP3A content, and is also highly expressed in the kidney. 3, 4 An extreme interindividual and interethnic variability for the expression of CYP3A5 has been reported. 5, 6 This difference is largely because of the A6986G polymorphism (rs776746) in intron 3, 5 in which the wild-type A allele and the variant G allele express CYP3A5*1 and CYP3A5*3, respectively. Whereas the *1 allele expresses the wild-type CYP3A5 protein, the *3 allele leads to splicing of an alternative exon that results in a premature stop codon and reduces CYP3A5 protein expression. 7 Thus, CYP3A5*1 and *3 represent the expressor and reduced expressor, which are the key determinants of the activity and expression of CYP3A5. CYP3A5 has recently been shown to regulate blood pressure. CYP3A5 is present in the kidney and converts cortisol and corticosterone to 6b-hydroxycortisol and 6b-corticosterone, respectively, which leads to sodium absorption and water retention at the renal tubules. 8 Thompson et al. 8 genotyped the CYP3A5*1/*3 polymorphism, which is likely to influence salt and water retention and risk for salt-sensitive hypertension. Previous publications have examined CYP3A5 polymorphisms in African Americans and Caucasians, and the *1 allele was repeatedly shown to be the risk allele for hypertension. [9] [10] [11] There are differences in the frequencies of this allele between racial groups. 5 Non-Caucasians have a higher prevalence of CYP3A5 expression and have different risks of diseases that are associated with the CYP3A5 expressor phenotype. However, there is no report to our knowledge that determined the effect of this variant on blood pressure in the Asian population. Replicating the result in different ethnic groups is important. Thus, in this study, we addressed the effect of the CYP3A5 A6986G polymorphism on blood pressure in Japanese. As the Japanese diet is characterized by a high consumption of salt, 12 we considered dietary salt intake as a potential modification factor when investigating the effect of genetic factor on blood pressure.
Materials and methods

Subjects
A cross-sectional study was conducted among 329 unrelated workers in a company in Kanagawa Prefecture of Japan, who underwent a health examination in 2003. Details of the study population were described elsewhere. 13 Owing to the small number of women (n ¼ 37), they were excluded from the analysis. We also excluded those who are currently under treatment for hypertension (n ¼ 38), diabetes (n ¼ 8) and hyperlipidemia (n ¼ 8). Accordingly, a total of 238 healthy Japanese men were enrolled in the genotype and phenotype association study and in the following interactive studies. The study was approved by the Ethical Committees of the Tokyo Medical and Dental University, and all participants provided written consent.
Methods
Details of medical history were obtained by interview. Height and weight were measured, and body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. Brachial blood pressure was measured using a posterior wall velocity/ankle-brachial index device (Nippon Colin, Aichi, Japan), after subjects rested quietly for at least 10 min in a supine position. Blood pressure was automatically measured twice and the average mean value was recorded. This device was used as it is approved by the US Food and Drug Administration as VP-2000/1000. Only data for blood pressure were used for the study.
The daily sodium intake of individuals was assessed by using a method to estimate 24-h urinary sodium excretion from a spot urine sample. Participants were asked to urinate and empty their bladder completely and a second morning 'spot' urine specimen was collected while they underwent the physical examination. All specimens were refrigerated at 4 1C within 24 h and frozen at À20 1C within 7 days. The sodium concentration of the spot urine sample was assessed by emission flame photometry Melting curve data were collected and classified using LightCycler genotype software; subjects with one lower Tm curve was identified as the AA (*1/*1) genotype, those with one higher Tm curve was identified as the GG (*3/*3) genotype and those with two curves were identified as AG (*1/*3) genotypes.
Statistical analyses
Hardy-Weinberg equilibrium for the distribution of genotype was determined by the w 2 -test. Analysis of variance was used to test differences of systolic blood pressure (SBP), diastolic blood pressure (DBP) and other continuous variables according to genotypes. Analysis of covariance was used to analyse the interactive effects of genotype, with estimated 24HUNaClV on blood pressure adjusted for age 
Results
The frequencies of CYP3A5 *3/*3, *1/*3 and *1/*1 genotypes were 43.3, 45.8 and 10.9%, respectively. The frequency of the *1 allele was 33.8%. The genotyping results were consistent with the HardyWeinberg equilibrium (P ¼ 0.722). The characteristics of subjects in different genotype groups are shown in Table 1 . There were no significant differences in mean age, BMI, spot urine Na excretion, spot urine creatinine excretion, estimated 24HUNaV and 24HUNaClV among genotype groups. The CYP3A5 genotype associated with DBP (Po0.05). The *1/*1 group has the highest DBP and exceeded that of the *3/*3 group by 7 mm Hg (P ¼ 0.038). The difference was strengthened after adjustment with age and BMI (*1/*1 vs*3/*3, P ¼ 0.007; *1/*1 vs*1/*3, P ¼ 0.045). SBP was not different among genotypes.
We then sought a potential interaction between the CYP3A5 genotype and 24HUNaClV on blood pressure levels using analysis of covariance (Table 2 ). Significant interactive effects between the CYP3A5*1/*3 genotype and 24HUNaClV on both SBP (P ¼ 0.046) and DBP (P ¼ 0.003) were detected. There were associations of CYP3A5*1/*3 genotypes with SBP (P ¼ 0.027) and DBP (P ¼ 0.001). Age and BMI were also associated with SBP (Po0.001) and DBP (Po0.001). 24HUNaClV did not associate with either SBP or DBP. Figure 1 shows the correlations of 24HUNaClV with SBP and DBP according to the CYP3A5 genotype using the general linear model. The slopes of the relationship between 24HUNaClV and blood pressure significantly differed between the two genotype groups (Po0.05). *3/*3 subjects had significantly increasing slopes of blood pressure with increasing 24HUNaClV (Figure 1a Next, the subjects were divided into high and low salt intake groups according to the median of 24HUNaClV. The ranges of 24HUNaClV in low and high groups were 3.12-9.91 g and 9.98-20.71 g, respectively. The differences in blood pressure between two 24HUNaClV levels according to the CYP3A5 genotype are shown in Figure 2 . In the low 24HUNaClV level, DBP was higher in the *1 carrier than in the *3/*3 genotype (P ¼ 0.006), the same trend of SBP was detected (P ¼ 0.095), whereas the difference was not detected in the high 24HUNaClV level. There was difference between two 24HU-NaClV levels in subjects with the *3/*3 genotype (DBP: P ¼ 0.024, SBP: P ¼ 0.064). This result was consistent with the former results analysed using continuous data.
Discussion
CYP3A5*1 and *3 have a significant difference in their allele frequencies among different ethnic groups. The CYP3A5*1 allele varies from over 45% in those of African descent to 8-15% in whites, and 23-40% in Asians. 15 This difference is thought to be an evolutional consequence for the need to retain water under different climates. 8 The association of CYP3A5 alleles with blood pressure has been initially studied in Blacks, in which the *1 allele is abundant. Givens et al. 9 found a significant association between CYP3A5*1/*3 and 16 also studied the population in Seychelles and found that age and urinary sodium excretion were significant effect modifiers of the association between the CYP3A5*1 allele and ambulatory blood pressure. As with Caucasians, a study conducted in Finland showed that the *1/*3 genotype had a significantly higher prevalence of hypertension than did the *3/*3 genotype. 10 To our knowledge, this genetic effect has not yet been addressed in Asians. Our study using apparently healthy Japanese men showed that the CYP3A5*1/*3 polymorphism associated with blood pressure, and that there was an interaction with salt intake. The *1/*1 genotype had a higher DBP than did the *3/*3 genotype, indicating that the genetic effect is more prominent on DBP in this population. When salt intake was taken into account, the interactive effect of genotype and salt intake was significant on both SBP and DBP. (SBP: Po0.046, DBP: Po0.003). As these effects remained significant after being adjusted for age and BMI, CYP3A5*1/*3 seems to be an independent modifier of individual salt sensitivity. These results are generally in the same line with previous reports that the *1 allele is a risk factor for hypertension.
In our study, DBP rather than SBP was strongly associated with the *1 allele. SBP is predominately determined by stroke volume, and thus, in theory, should be more influenced by CYP3A enzyme activity. However, in our study population, DBP gave a positive association, but SBP only gave a weak trend with the increased amount of *1 allele (0 allele: 133.5 ± 16.4, 1 allele: 134.8 ± 18.0 and 2 alleles: 138.8±20.6 mm Hg).
Further investigation taking the environmental factor of salt intake into account led us to find different reactions of the CYP3A5 genotypes on blood pressure. To our surprise, the blood pressureelevating effect was more prominent in *3*3 subjects than in *1 carriers. In two previous reports, *1 carriers have been shown to express more enzyme and to be salt sensitive than *3*3 subjects. 11, 16 Our results point to an opposite direction. Potential explanations for this discrepancy are as follows: two former studies were conducted in Blacks, not in Asians, and one possibility is the difference in diet. The salt intake in the Black population may be low because of more vegetables and less processed food. 17 In such a case, the CYP3A5 expressor may become more sensitive to salt. In contrast, Japanese diet is abundant in salt and the dietary salt intake usually exceeds 10g day À1 (the median of our study group was 9.98g day
À1
). Under such a habitual high-salt diet, the blood pressureelevating effect of CYP3A5 in *1 carrier might have already saturated. Thus, in only the CYP3A5 low expressor (*3*3) might the salt sensitivity become overt. To support this notion, it was reported that, although *1 carriers express large amounts of CYP3A5 mRNA and protein, *3 carriers also produce small amounts of normally spliced CYP3A5 mRNA and resulting protein. 18 On the basis of studies in a spontaneous hypertensive rat model, excessive intrarenal conversion of cortisol to 6b-hydroxycorticosterone by CYP3A isoenzymes is thought to mediate tubular sodium reabsorption, which leads to blood pressure increase. 19 On the other hand, functional studies in epithelial kidney cells have indicated a role of CYP3A5 in 6b-hydroxysteroid formation, which may, in contrast, counteract with the mineralocorticoid receptor from being activated. The presence of a hypothetical second enzyme might provide an additional pathway to the mineralocorticoid receptor from being occupied by cortisol. 20 Such a hypothesis could potentially explain the diminished salt sensitivity of blood pressure in *1 carriers compared with *3*3 subjects as shown in our results.
Hypertensive subjects were excluded from this study, as dietary salt restriction and using antihypertensive drugs might affect the results. It is possible that the AA genotype might be a stronger predictor of higher SBP and DBP in hypertensive subjects. Salt sensitivity of blood pressure is more Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure; 24HUNaCl, calculated 24-h urinary NaCl excretion value. The CYP3A5*1 carriers is the reference group. The interaction between the 24HUNaClV and CYP3A5*1 carriers is the reference group. b values and 95% CI were derived from multiple regression analysis models adjusted for age and BMI. CYP3A5*1/*3 polymorphism was assigned as: CYP3A5*3/*3 ¼ 1; CYP3A5*1 carriers ¼ 0.
CYP3A5, salt intake and blood pressure L Zhang et al frequent in hypertensive than in normotensive subjects. 21 It is estimated that 26% of Americans with normal blood pressure and about 58% of those with high blood pressure may be salt sensitive. 22 This could also be true for salt sensitivity of blood pressure in hypertensive subjects. Further study is needed to clarify the effect of the CYP3A5 polymorphism on salt sensitivity in primary hypertensives.
It is obvious that salt sensitivity of blood pressure is not accounted for by a single gene, but rather various genetic and environmental factors are involved. Recent studies have identified that there is gene-gene-environment interaction between CYP3A5, ABCA1 and salt intake. 23 More biophysiological pathways may be involved in the homoeostasis of sodium retention and blood pressure regulation, which acts along with the increase in salt intake. It is conceivable that there might be genetic or environmental factors still undiscovered, which could change the direction of the effect of a certain variation in different ethnic groups. Further studies are definitely warranted to provide a more comprehensive explanation for the basis of our observation.
In conclusion, our study using Japanese men showed that CYP3A5*1*3 is a modifier of blood pressure by changing salt sensitivity. Although the CYP3A5*1 carrier tends to have higher blood pressure, the blood pressure of CYP3A5*3 homozygous is more vulnerable to salt intake. The physiological role of these variants needs to be further studied under the context of wider genetic and environmental influences. The difference in blood pressure between the CYP3A5*3/*3 group and the *1 carriers group in the low 24HUNaClV level (P ¼ 0.095 in SBP; P ¼ 0.006 in DBP).
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The difference in blood pressure between two 24HUNaClV levels in the *3/*3 group (P ¼ 0.064 in SBP; P ¼ 0.024 in DBP).
What is known about this topic K CYP3A5*1/*3 polymorphism is the key determinant of the expression of CYP3A5, which has an extreme interindividual and interethnic variability. K CYP3A5*1/*3 polymorphism influence salt and water retention and is one of the candidate genes for salt-sensitive hypertension.
What this study adds K CYP3A5*1 allele is strongly associated with diastolic blood pressure rather than systolic blood pressure in Japanese males. K CYP3A5*1*3 gene polymorphism is a modifier of blood pressure by changing salt sensitivity. K Although CYP3A5*1 carrier tends to have higher blood pressure, the blood pressure of CYP3A5*3 homozygous are more vulnerable to salt intake.
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